ArticleAnnals of translational medicine2020

PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer.

Ziyi Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.